Flow Cytometry Market To Surpass US$ 9.3 Billion By 2027| Coherent Market Insights
Flow Cytometry Market |
The need for disease diagnosis
and progress in flow cytometry technology are both anticipated to fuel market
growth over the forecast period. To reach the emerging markets, manufacturers
are concentrating on technological advancements in flow cytometry. For
instance, in August 2017, the U.S. Food and Drug Administration (FDA) approved
Beckman Coulter Life Sciences' most recent clinical flow cytometry product, the
Navios EX flow cytometer, for use in clinical laboratories in the United
States. In addition, as part of its mission to provide cutting-edge clinical
laboratory products, Sysmex America, Inc. introduced CyFlow Antibodies in
October 2017—a comprehensive portfolio of Analyte Specific Reagent (ASR)
antibodies for use in flow cytometry applications.
Major players are also
concentrating on product launches in order to diversify their product offerings
and to improve their market positions. For instance, Becton, Dickinson and
Company (US) released its FlowJo software version 10.6 in June 2019 for the analysis
of flow cytometry data. This software can be further integrated with BD
FACSDiva to increase its capabilities for the comparison of data from various
flow cytometry runs in a single view and the analysis of multiple flow
cytometry runs.
In 2018, The Flow
Cytometry Market Was Valued At US$3,886.1 Million, And It Is
Anticipated To Grow At A CAGR Of 10.2% Between 2018 And 2023. (2019-2027).
Analyzing the expression of cell
surface and intracellular molecules is made easier by flow cytometry. It helps
evaluate the purity of isolated subpopulations and is used to define and
characterise various types of cells in a heterogeneous cell population. The
market is being driven by increased R&D efforts by several key players for
the creation of multicolor assays and cutting-edge analytical reagents. The
market for flow cytometry has experienced rapid growth as a result of the
rising prevalence of chronic and infectious diseases, including the COVID-19
outbreak. Following the outbreak, a large number of academic institutions and
pharmaceutical firms are engaged in extensive research and development
(R&D) activities for the creation of new vaccines and treatments. Due to
this, there is a great need for flow cytometry applications in research.
Cancer and immunodeficiency are
two conditions that are frequently diagnosed using flow cytometry. One of the
elements anticipated to propel the market for flow cytometry over the forecast
period is the rising prevalence of these diseases. Additionally, the negative
effects of chemotherapy and radiation therapy in the treatment of cancer have
led doctors to prefer autologous and allogeneic stem cell therapies more,
positively influencing the development of this market.
Due to rising healthcare costs in
developed nations and bettering healthcare infrastructure, the biotechnology
industry is anticipated to experience significant growth during the forecast
period. The market is anticipated to be driven by an increase in government
funding for clinical studies involving in vitro molecular diagnostics, as these
studies are essential to the creation of new products. Significant market
growth has been fueled by rising investments in well-known biotech and
biopharma companies.
Top companies involved are- Becton Dickinson and Company, General
Electric Company, Luminex Corporation, Thermo Fisher Scientific, Inc., Bio-Rad
Laboratories, Inc., Miltenyi Biotec GmbH, Merck & Co Inc., Sysmex
Corporation, Agilent Technologies, Inc., and Danaher Corporation.
Get Press
Release of Flow
Cytometry Market
Comments
Post a Comment